AU Patent

AU2023266354A1 — Compositions and methods for inhibiting expression of the ALAS1 gene

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2023-12-07 · 2y expired

What this patent protects

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. 20378020_1 (GHMatters) P102746.AU.2

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. 20378020_1 (GHMatters) P102746.AU.2

Drugs covered by this patent

Patent Metadata

Patent number
AU2023266354A1
Jurisdiction
AU
Classification
—
Expires
2023-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Icahn School of Medicine at Mount Sinai
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.